Skip to content

Mechanistic Study of BuShenQuXie Formula in Treating Renal Fibrosis via Modulation of Gut Microbiota Function and Inhibition of the Wnt/ß-Catenin Pathway

Mechanistic Study of BuShenQuXie Formula in Treating Renal Fibrosis via Modulation of Gut Microbiota Function and Inhibition of the Wnt/ß-Catenin Pathway

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002558
Enrollment
Unknown
Registered
2025-12-27
Start date
2025-09-30
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Stage 2–4 CKD patient group:All enrolled patients will receive standard symptomatic Western medical treatment, including control of blood pressure, blood glucose, blood lipids, and uric acid
management of anemia
correction of electrolyte and acid–base imbalances
regulation of calcium–phosphorus metabolism
and active prevention and treatment of complications and comorbidities. For Traditional Chinese Medicine (TCM) therapy, patients will be treated with Professor Shudong Yang's self-designed Bushen Qux
one pack taken at a time, morning and evening. All decoctions will be prepared by the Pharmacy Department of Shenzhen Traditional Chinese Medicine Hospital. The treatment course will last for 8 weeks.

Sponsors

Shenzhen Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients meeting the diagnostic criteria for CKD stage2-4; (2) Aged =18 and =65 years; (3) Not receiving hemodialysis or peritoneal dialysis.

Exclusion criteria

Exclusion criteria: (1)Current use of glucocorticoids or immunosuppressive agents. (2)Presence of severe comorbidities in other organ systems, including but not limited to heart failure, or dysfunction of the respiratory, digestive, or hematopoietic systems. (3)Recent history of surgery, severe infection, or malignancy. (4)History of organ or bone marrow transplantation. (5)Acute kidney injury secondary to primary disease or drug exposure. (6)Pregnant or lactating women. (7)Participation in another clinical trial involving investigational drugs. (8)Use of antibiotics within 4 weeks prior to enrollment. (9)Consumption of yogurt, probiotics, or other products/medications that may alter gut microbiota within 1 week prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Serum creatinine;

Secondary

MeasureTime frame
Blood urea nitrogen;Bowel movement frequency;Stool consistency and form;Fecal metabolomic and genomic analysis;

Countries

China

Contacts

Public ContactSHUDONG YANG

Shenzhen Traditional Chinese Medicine Hospital

shudong_yang@126.com13688806568

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026